ArticleDrug discovery today. Disease mechanisms2007
Mechanisms of sepsis and insights from clinical trials.
Article in Drug discovery today. Disease mechanisms, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- A FHIR-Powered Python Implementation of the SENECA Algorithm for Sepsis Subtyping.Applied clinical informatics · 2025Article
- A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- Lipidomics in translational research and the clinical significance of lipid-based biomarkers.Translational research : the journal of laboratory and clinical medicine · 2017Review
- Kaempferol and Chrysin Synergies to Improve Septic Mice Survival.Molecules (Basel, Switzerland) · 2017Article
- Why a second look might be worth it: immuno-modulatory therapies in the critically ill patient.Journal of thoracic disease · 2016Article
- Milk fat globule epidermal growth factor-factor 8-derived peptide attenuates organ injury and improves survival in sepsis.Critical care (London, England) · 2015Article
- Lipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides.Scientific reports · 2015Article
- Lack of new antiinfective agents: Passing into the pre-antibiotic age?World journal of biological chemistry · 2015Article
- Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.Physiological reviews · 2013Article
- Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors.Antimicrobial agents and chemotherapy · 2013Article
- Chitohexaose activates macrophages by alternate pathway through TLR4 and blocks endotoxemia.PLoS pathogens · 2012Article
- Article
- Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target.British journal of pharmacology · 2010Review
- Saponin fraction from Astragalus membranaceus roots protects mice against polymicrobial sepsis induced by cecal ligation and puncture by inhibiting inflammation and upregulating protein C pathway.Journal of natural medicines · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Multiple clinical trials of adjunctive therapy for sepsis and septic shock have been conducted to neutralize bacterial components or to modulate host inflammatory responses to infection but with limited success. Many therapies are only beneficial only in patients with a high severity of illness and have minimal or harmful effects in patients that are less severely ill. Improved measures of severity of illness and discovery of biomarkers to help identify these high-risk patients are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.